semaglutide high heart rate cardiovascular outcomes align more closely with attained dose than achieved weight loss Increased heart rate : r/Semaglutide

Renal adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS) between December 2003 and December 2024 were analyzed using the validated OpenVigil 2.1 platform

More long-term studies are warranted to evaluate whether the same daily dose in different formulations leads to distinct increases in muscle carnosine content

That makes it a weaker choice for multi-use storage windows

The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg